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Transdermal delivery of tolterodine tartrate for overactive
bladder treatment: In vitro and in vivo evaluation
The purpose of the study was to develop a transdermal tolte-
rodine tartrate (TT) patch and to analyse its effi  cacy for 
overactive bladder (OAB) treatment. Patches were prepared 
using various polymers and plasticizers via the solvent 
casting method. The patches were characterized for tensile 
strength, thickness, moisture content, modulus of elasticity 
and water absorption capacity. Diff erential scanning calo-
rimetry and Fourier transform infrared analyses were also 
performed. To determine patch eff ectiveness, in vitro re-
lease, permeation and animal studies were performed. The 
patches showed satisfactory percentage of release, up to 
89.9 %, and their mechanical properties included thickness 
(0.10–0.15 mm), tensile strength (4.62–9.98 MPa) and modu-
lus of elasticity (20–29 MPa). There were no signifi cant in-
teractions between TT and other excipients. Animal studies 
indicated that the TT patch reduced the incidence of side 
eff ects; however, studies of longer duration are required to 
determine the eff ectiveness in treating OAB.
Keywords: tolterodine tartrate, transdermal, overactive 
bladder, matrix patches, permeation
The International Continence Society (ICS) defi ned overactive bladder (OAB) as „a 
collection of symptoms suggestive of lower urinary tract dysfunction such as urgency, 
with or without urge incontinence, normally accompanied with frequency and nocturia” 
(1). The National Overactive Bladder Evaluation (NOBLE) study reported that OAB aff ects 
approximately 16 % of the population (2) and aff ects the quality of life of patients. Pharma-
cological anti-muscarinic molecules like trospium, oxybutynin and tolterodine tartrate 
(TT) are used in the treatment of this chronic condition (3). However, oral administration 
exposes patients to side eff ects such as headache, constipation and dry mouth (4). To mini-
mize these side eff ects and to improve compliance, transdermal delivery is a promising 
alternate route (5). Th is non-selective, competitive anti-muscarinic agent, TT, is recom-
mended as a fi rst-line pharmacological treatment for OAB (6). Upon administration, TT is 
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methyl derivative (7, 8). The drug has in vivo functional selectivity for muscarinic receptors 
in the bladder over the salivary glands and hence it is suitable for the treatment of OAB (9, 
10). Transdermal delivery allows superior control of systemic drug concentration, by-pass-
es fi rst pass metabolism, minimizes gastrointestinal side eff ects, allows immediate termi-
nation of administration in case of toxicity and greatly improves patient compliance (11–
13). Zhao reported that the fl ux of TT solution was not aff ected by addition of 
O-acylmenthol derived chemical enhancers but skin reservoir eff ects of enhancer-contain-
ing groups showed promising results compared to the control group (14). Choi reported 
that free base TT penetrated hairless mouse skin about 10 times more eff ectively compared 
to other lipophilic salt forms (15). Elshafeey et al. developed controlled release of the drug 
into the systemic circulation with the use of TT microemulsion, which was advantageous 
in prevention of nocturnal enuresis with improvement in patient compliance (16). Similar 
studies of both oxybutynin and TT proniosomal gel were reported by our group to be suit-
able for transdermal route, which reduced the dry mouth eff ect compared to the oral route 
in our earlier studies (17, 18). The drug had not been explored for transdermal delivery as 
a patch and this is the fi rst study that analyses the effi  cacy of this formulation. The main 
aim of this research is to formulate a TT transdermal matrix patch possessing desirable 
physicochemical, release and permeation characteristics with reduced side eff ects as well 
as increased effi  cacy for OAB.
EXPERIMENTAL
Materials
TT was a gift  from Aurobindo Pharmaceuticals (India). Eudragit E 100, RS100, RL100, 
RSPO and RLPO were gift s from Evonik Röhm GmbH, Germany. EUDRAGIT® polymers 
are copolymers derived from esters of acrylic and methacrylic acid whose physicochemical 
properties are determined by functional groups. In these studies, Eudragit E 100 is a cat-
ionic polymer with dimethylaminoethyl methacrylate as a functional group. Other Eu-
dragit grades such as RS100, RL100, RSPO and RLPO are ethyl acrylate, methyl methacry-
late copolymers with trimethyl-ammonioethylmethacrylate as diff erent ratios of the 
functional group. Polyvinyl pyrrolidone (Kollidon® 30) was procured from the BASF 
Chemical Company, Germany. Dibutyl phthalate (DBP) was purchased from Qualigens 
Fine Chemicals, India. Triethyl citrate (TEC) was purchased from Merck Chemicals, Ger-
many. Dibutyl Sebacate (DBS) was purchased from Sigma-Aldrich Chemie GmbH, Ger-
many. All other chemicals used in the study were of analytical grade and were used as 
received.
Preparation of patches
The polymeric matrix formulation was prepared by dissolving diff erent grades ( E 
100, RSPO and RLPO) of Eudragit polymers (200-400-600 mg) in chloroform, then 100 mg 
PVP was added under uniform stirring for 15–20 min. The patches were formed using the 
solvent casting method. To the above solution, one of the plasticizers (DBS/DBP/TEC) at 
either 10 or 15 % of total polymer mass and 8 mg of TT were added at room temperature 
under uniform slow stirring. The resulting solution was poured into casts that had an alu-
minium foil backing layer. It was drie d for 24–48 h at room temperature (19). Table I con-
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tains details of the various formulation combinations. All formulations with the codes 
starting with A (A1, A2, A3) were designated as series A. All other series were similarly 
categorised into series B to F.
CHARACTERISATION OF TRANSDERMAL PATCHES
Patch thickness and tensile strength
A digital micrometer (Mitutoyo, Japan) was used for determining patch thickness 
(Table I). Tensile strength was measured with a load of 50 kN at 5 mm/min extension speed 
using an Instron  4204, UK tensilometer. The test was performed according to the D 882 – 
75D method of the American Society for Testing Materials (ASTM) for 6 samples of each 
formulation patch. Temperature of 25 ± 2 °C and humidity of 56 ± 2 % were maintained 
throughout the test (19).







where τ is tensile strength; Lmax is maximum load and Ai is the initial cross-sectional area 
of the sample.
Modulus of elasticity determination
The modulus of elasticity refl ects the stiff ness or elasticity of transdermal patches. 
This indicates the resistance to distortion of the fi lms and was calculated by plott ing the 
stress strain curve using an Instron 4204, UK tensilometer. The modulus of elasticity is 
represented as the ratio of applied stress over strain in the region of elastic deformation 
and was determined using the following formula (2):
 E = stress/strain (2)
Moisture content
Matrix patches were independently weighed and preserved in a desiccator for a day 
at 40 °C. They were consecutively reweighed until a constant mass was established. The 
initial and constant fi nal patch mass diff erence was noted to calculate the moisture content 
percentage. Six readings were recorded and the average was calculated as described by 
Rajabalaya et al. (19).
Water absorption
Water absorption capacity was determined by weighing the dry patches initially. 
They were then kept at two diff erent relative humidities for 24 hours at room temperature. 
Saturated sodium chloride solution and saturated ammonium hydrogen phosphate solu-
tion had yields of 75 and 93 % humidity, respectively. Patch mass was recorded periodi-
cally until it was constant. Average of six readings was recorded (Table I) (19).
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Fourier Transform Infrared (FTIR) studies
Tolterodine tartrate, PVP, E 100 and their combination are depicted in Fig. 1a, while 
TT, RLPO, RSPO, PVP, TT and their combination are represented in Fig. 1b. Each compo-
nent was mixed individually with KBr (IR grade) in the 100:1 ratio and pressurized using 
a hydraulic press to obtain pellets. These were scanned using an FTIR spectrophotometer 
in the range of 4000–400 cm–1 (FT-IR 8400S, Shimadzu, Japan).
In vitro release studies
Franz (vertical) Diff usion Cells (PermeGear, USA) were used for in vitro studies. A 1.7 
cm2 diameter matrix patch was placed carefully, with the backing membrane facing the 
atmosphere, on the receptor compartment that contained phosphate buff ered saline (PBS) 
at pH 7.4. The assembly was maintained at a uniform temperature of 32 ± 0.5 °C with uni-
form stirring speed of 50 rpm. Diff usion of the drug from the matrix patch was ensured 
by placing the drug side in contact with PBS in the receptor compartment. Every hour, 1 
mL of the receptor sample was withdrawn and the same volume of buff er solution was 
replaced. The sample was measured using reverse-phase HPLC (1200 HPLC series; Agilent 
Technologies, Santa Clara, CA, USA) with a C-18 analytical column (5 μm, 4.6 × 150 mm; 
Phenomenex, Torrance, CA, USA). The sample was measured in UV at a 281 nm wave-
length with 35:65, V/V of mobile phase (20 mM pH 3.0 acetate buff er/methanol) at an elu-
tion rate of 1 mL min–1. The retention time was 5.5 min (15).
Release kinetics data treatment
Various kinetic models, zero order, fi rst order Higuchi and Korsmeyer-Peppas were 
applied to the in vitro release data. These models serve to predict the release mechanism 
and kinetics of the drug from the transdermal matrix patch (Table II).
In vitro permeation studies
Sprague Da wley rats (n = 6) were used in the study. Each rat was sacrifi ced as per the 
cervical dislocation method protocol. A section  of the freshly excised abdominal rat skin 
treated in isotonic solution was bound intimately with a transdermal patch to the donor 
compartment without any air gap between the drug side of the patch and the stratum 
corneum side of the skin. The dermal side of the skin just touched the receptor liquid sur-
face horizontally to allow drug permeation. The receptor compartment temperature, vol-
ume of sample collection and method of analysis were similar to the in vitro release study 
(17, 20). The Internat ional Medical University (IMU) Research Ethics Committ ee (B0109_
Res182012) approved the procedures and animal care for the experiments undertaken in 
this project including pharmacological experiments. Percentage of permeation and perme-
ation rate were calculated and are given in Table III.
In vivo animal studies
Acetic aci d (ACA)-induced bladder hyperactivity
Male Sprague Dawley (SD) rats, initial mass 350–450 g, were used in the experiment. 
Rats were housed in the Animal Holding Facility (AHF) of the International Medical Uni-
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versity (IMU). They were housed in plastic cages, 3 rats per cage. The environment was 
maintained at ambient temperature with a 12 h light/12 h dark cycle. All rats were allowed 
free access to normal commercial rat feed pellets (Gold Coin Feedmills, Malaysia Sdn. Bhd) 
and reverse osmosis (RO) water. Rats were acclimatized for one week prior to experimental 
protocols. All the experimental procedures were performed in accordance with the guide-
lines issued by the International Medical University Joint Committ ee (IMU-JC) for Ethics.
Bladder infl ammation caused by the administered ACA solution (0.75 %) was evalu-
ated histopathologically. A urinary catheter was used to administer the solution to uncon-
scious rats. This model produces micturition due to the acute infl ammation caused in the 
urinary bladder by ACA (21).
Measurement of salivary secretion
The experiment was conducted on diethyl ether anesthetized rats (21). Cott on balls 
(3–5) were kept for 10 mins for saliva absorption; they were immediately weighed to avoid 
moisture loss. Both oral and patch treatments were given at 0 hour along with the pilocar-
pine injection. The amount of saliva collected in the cott on balls was measured at 2, 4, 12 
and 24 h (17, 21).
Histological studies
Aft er the treatment period, each rat was anaesthetized and sacrifi ced as per protocol. 
The bladder was reached aft er dissecting the abdomen wall and exposing the peritoneum 
space. The bladder dome was dissected down to the level of ureteral insertion. The excision 
was done as a total cystectomy procedure involving ligating at the level of pelviureteric 
junction above and urethra below. This ensured that all 3 layers, urothelium, lamina pro-
pria and muscle layers were intact for the study. Bladders were fi xed in 10 % buff ered 
formalin overnight, processed, embedded in paraffi  n, and cut into 5-μm slices. All stain-
ing was done on at least two diff erent areas of the bladder. These were then observed un-
der a light microscope aft er hematoxylin and eosin staining (17).
Statistical analyses
SPSS v18.0 (IBM Corp., USA) statistical soft ware was used for data analysis. Paired t-
test and analysis of variance were both performed. p < 0.05 was considered signifi cant. 
Values are expressed as mean ± standard deviation.
RESULTS AND DISCUSSION
Diff erent grades of Eudragit polymers, PVP, diff erent categories of plasticizers, such 
as dibutyl sebacate (DBS), dibutyl phthalate (DBP) and triethyl citrate (TEC), used for the 
preparation of patches are presented in Table I. Mechanical properties of the matrix patch 
such as modulus of elasticity, tensile strength and thickness are also given in Table I.
Thickness and tensile strength
TEC is the most hygroscopic plasticizer and is followed by DBP and DBS; therefore, 
patches containing TEC (A3) had the highest thickness amongst series A, with E 100 fol-
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lowed by DBP and DBS containing patches (22). Correspondingly, B3 and C3 had the highest 
thickness in their respective series. Likewise, similar observations were made with other 
Eudragit polymer grades (RSPO/RLPO) of D and E series patches. A tensile strength of 4 
MPa and above is desirable for transdermal patches according to the American Society for 
Testing and Materials (ASTM) guidelines (23). The data revea led that the average tensile 
strength of all the patches was in the range of 4.09 to 9.98 MPa, indicating good tensile 
strength. This can be illustrated with E3 having 4.09 MPa, which is the least in series E (22). 
DBS patches (Ex: A1 – 9.98 MPa) always maintained the highest tensile strength among their 
respective series compared to those of the other two plasticizers, while patches with DBP 
exhibited a higher modulus of elasticity (22.73 to 29.48 MPa) than the other two plasticizers.
Patch thickness increased in the formulations containing hydrophilic polymers such 
as PVP, RLPO and Eudragit RL100, as evidenced in Table I. Patch thickness in Eudragit 
E 100 series is the lowest compared to other series patches containing an additional PVP 
(B and C series). In contrast, the results of tensile strength of matrix patches decreased with 
an increase in the amount of PVP in the patches. Increase in the percentage of plasticizer 
from 10 to 15 % r educed the tensile strength of patches, as observed in the C and F series. 
The hygroscopi c nature of PVP may have increased the matrix patch bulkiness in the B 
and C series, as witnessed by lesser patch thickness with 100 mg PVP compared to patch-
es with 200 mg (24). Similarly, the hygroscopic nature of the plasticizer was also respon-
sible for higher thickness of the patches.
The tensile strength data supports the possibility of polymer- polymer bond strength 
decrease due to the disruption in continuity of polymer chain molecules (19). The molecu-
lar weight of the plasticizer also aff ects the tensile strength of matrix patches (25). The 
descendi ng order of plasticizer molecular weight used in this study is DBS>DBP>TEC. Low 
molecular weight plasticizers increase the plasticizing eff ect by increasing the space be-
tween the polymeric chains, thus reducing the tensile strength. Optimal tensile strength 
for the patch is necessary to keep the patch on the skin and withstand the movements of 
daily life. The prepared patches had the necessary tensile strength for everyday wear.
Moisture content and water absorption studies
Moisture content of patches with hydrophilic excipients (PVP and RLPO) was higher 
compared to that of hydrophobic nature polymeric patches ( E 100 and RSPO). Matrix patch-
es with TEC (A3, B3, C3, D3, E3 and F3) exhibited increased water absorption capacity in 
both 75 and 93 % RH due to the hygroscopic nature of TEC. Higher amount of PVP (200 
mg) accounts for the higher moisture content of the PVP containing patches, namely, F3 
with 0.881 % (m/m). Both B and C series had lower and higher PVP content, respectively, 
and exhibited proportionate water absorption capacities with B having lower capacity. A 
similar patt ern was displayed by the E and F series (22). Hydrophilic plasticizer TEC was 
also responsible for higher moisture uptake and water absorption capacity. Moisture con-
tent and water absorption capacities of the E 100 patches were dependent on the concentra-
tion of plasticizer and PVP used in the study (26). Water absorption under both of the 
relative humidity conditions was higher with higher PVP contents, because it allowed 
water molecules to easily migrate into the matrix system, which led to increased moisture 
uptake as well as absorption of water (25). Hydrophobic DBS containing patches are tough 
to hydrate, especially at 15 %. It is clear from Table I that the patches remained intact and 
stable during and aft er water uptake capacity studies.
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Fourier Transform Infrared (FTIR) studies
FTIR spectra (Fig. 1a,b) of individual polymers (Eudragit E 100, RSPO and RLPO) and 
PVP and TT including a combined mixture of E 100/PVP/TT; RSPO/RLPO/TT were com-
pared for changes in spectral shift s in the mixture. FTIR spectra of the E 100/PVP, RSPO/
RLPO and the drug TT combined mixture are shown in Fig. 1a,b. All peaks of the polymers 
used in the mixture were observed in the FTIR spectra. FTIR spectra of the drug and com-
bined mixtures revealed the following bands: –OH stretching at 3437.50 cm−1, –C-H stretch-
ing (aromatic) at 3050.83 and 3027.33 cm−1, –CH3 stretching (aliphatic) resulting in 2695.11 
and 2924.92 cm−1, C=C stretching (aromatic) resulting in 1600.34 and 1452.95 cm−1. Polymer 
and drug compatibility is of the paramount importance. The FTIR study clearly showed 
that there were no signifi cant spectral shift s in peaks corresponding to diff erent Eudragit 
polymers or the drug (19). There were, however, a few overlaps in characteristic peaks of 
the drug and the polymer. This confi rms that there were no interactions and indicates the 
compatibility of the drug with other components.
In vitro release studies
The 8-h cumulative re lease (%) of the matrix patches is shown in Fig. 2. The fi gure 
depicts an increase in the release percentage with an increase in matrix patch plasticiser 
percentage for the DBS containing patches. However, in the case of E 100 based matrix 
Fig. 1. FTIR spectra for: a) E 100, PVP, tolterodine tartrate and combination, b) RLPO, RSPO, toltero-
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patches containing DBS or DBP as plasticizer, the release was signifi cantly lower without 
PVP (A1, 22.82 %) compared to that of the PVP comprising patch (B1, 33.65 % and C1, 89.90 
%). Series D, E and F (D1, E1 and F1) containing RSPO and RLPO polymers with DBS as 
plasticizer (D1, 48 %, E1, 79.7 % and F1, 74.6 %) showed a higher percentage of drug release 
compared to the DBP patches (D2, 34.3 %, E2, 40.5 % and F2, 53 %). The TEC containing 
patches (D3, 44.64 %, E3, 41.09 % and F3, 49.03 %) had higher drug release compared to (D2, 
E2 and F2) DBP containing patches. In vitro release studies were conducted to ascertain the 
drug diff usion patt ern from the matrix patches. The following interesting discussion could 
be drawn from the observed results. The percentage of release of TT was higher with PVP 
containing patches, this may be due to the dissolution of hydrophilic PVP in the buff er 
medium, forming pores on the matrix patch and leaching the drug from the formulation 
into the solution, thus increasing the rate of diff usion into the patch (19).
It is not only the PVP but also the plasticizer that infl uences the drug release behav-
iour in the transdermal delivery system from matrix patches. An increase in the number 
of plasticizer molecules between polymer chains reduces the inter-molecular att ractive 
forces between the polymer chains, thus leading to easy  diff usion out of the matrix patch. 
According to the report by Siepmann et al. (27), while DBS is the right plasticizer for fast 
release, DBP should be selected for more prolonged drug release. The hydrophilic TEC 
plasticizer tends to absorb moisture and leach it out from the matrix patch, leading to 
disruption of polymeric chain integrity resulting in pores and reduction of plasticizer 
content, which increases drug diff usion out of the matrix patch (22); in contrast, DBP is 
hydrophobic and yields the opposite eff ect.
Release kinetics data treatment
As regards release ki netics, the best-fi t was found with Higuchi’s model, which calcu-
lates mass transport processes using the fi rst-order release kinetics equation. All the n-
values for formulations containing plasticizer TEC exceeded 0.89, which suggests either 



























Time (t1/2) Time (t1/2)
334
R. Rajabalaya et al.: Transdermal delivery of tolterodine tartrate for overactive bladder treatment: In vitro and in vivo evaluation, Acta 
Pharm. 67 (2017) 325–339.
 
Case-2 relaxation or super Case-2 transport of polymeric chain erosion (Table II). The Hi-
guchi model is established on the hypotheses that the initial drug concentration in patch-
es is higher than its solubility in the receptor and that the swelling of matrix patches and 
dissolution rates are negligible (28). Results showed that formulations containing plasti-
cizer DBS followed the Higuchi release model. According to the Higuchi model, the DBS 
formulations followed a diff usion controlled drug release mechanism.
In vitro permeation studies
Series C and E were selected for in vitro permeation studies based on the above excel-
lent physicochemical, mechanical and in vitro release characteristics of transdermal patch-
es. As shown in Fig. 3, formulations C1 and E1 showed the highest cumulative percentage 
of drug permeation, 63.07 and 63.25 %, respectively. The initial rapid release (burst eff ect) 
was due to rapid movement of the drug from the surface of the matrix. Aft er the burst ef-
fect, the drug was released gradually at a regular pace, achieving a controlled release state. 
In vitro permeation study exhibited concentration dependent kinetics. Amongst all formu-
lations, the two formulations tested for salivary secretion, the fi rst with E 100 and higher 
PVP content and the second with the RSPO-RLPO combination with PVP (C1 and E1) 
showed rapid initial permeation (Fig. 3), which is desirable for transdermal delivery. Both 
parameters, the gradient of drug concentration as well as the vehicle-membrane partition 
coeffi  cient were infl uenced by the extent of drug solubility in the vehicle (16, 19). The per-
meation percen tage and permeation rate for the selected formulations (C1 and E1) showed 
higher rapid initial permeation and permeation rate (Table III: 4.23 and 3.47 μg cm–2 h–1, 
respectively) compared to other formulations. Hence, these two formulations were chosen 
for further in vivo animal studies.
Table II. Release kinetics data treatment
Model A1 A2 A3 B1 B2 B3 C1 C2 C3
Zero order 0.9524 0.9679 0.9901 0.9649 0.9402 0.9901 0.9239 0.9919 0.9922
First order 0.9662 0.9775 0.9925 0.9824 0.9558 0.9727 0.9720 0.9790 0.9125
Higuchi 0.9856 0.9818 0.9231 0.9810 0.9817 0.8653 0.9971 0.8979 0.9062
Korsmeyer Peppas 0.9900 0.9926 0.9913 0.9847 0.9727 0.9865 0.9954 0.9942 0.9949
n value 0.6600 0.6110 0.9650 0.6426 0.5676 1.0710 0.4998 0.1052 0.9431
Model D1 D2 D3 E1 E2 E3 F1 F2 F3
Zero order 0.8313 0.7751 0.8978 0.9094 0.9186 0.8956 0.9695 0.9764 0.9332
First order 0.8564 0.8156 0.9128 0.9330 0.9171 0.9329 0.9116 0.9680 0.9672
Higuchi 0.9092 0.9510 0.9341 0.9910 0.9276 0.9661 0.9363 0.9667 0.9800
Korsmeyer Peppas 0.8818 0.9430 0.8956 0.8460 0.9820 0.8679 0.9169 0.9814 0.9455
n value 0.6678 0.3736 0.4857 0.9857 0.4800 0.4359 0.9951 0.6807 0.4774
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In vivo animal studies
Salivary secretion
Based on the results of mechanical, physicochemical and in vitro release/permeation 
study, patches C1 and E1 were selected for the in vivo animal study. Whole saliva secreted in 
the oral cavity in 10 minutes was collected aft er 15 minutes of pilocarpine stimulation. Aft er 
1 and 12-hour administration of oral TT, there was a 1.68 and 2.39 fold decrease in whole 
saliva secretion, respectively, compared to control rats (Fig. 4a,b). This shows that oral TT 
markedly suppresses pilocarpine-stimulated salivation. Salivary secretion studies indicated 















Fig. 4. Salivary secretion in rats with various formulations over 24 hours: a) control (no TT treatment) 
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higher activity of oral TT in the salivary gland than the transdermal matrix patch containing 
TT (10). A decrease was observed in the total amount of saliva collected in the second hour 
aft er patch administration, demonstrating that transdermal TT exerted a lesser eff ect on 
salivary glands than oral administration. The main salivary secretion of transdermal ap-
plication produced lower suppression of pilocarpine-stimulated salivation. The results 
showed that the suppression of pilocarpine-stimulated salivation was greatly reduced aft er 
12 h of removal of both of the matrix patch formulations. These observations demonstrate 
the advantages of the TT containing transdermal patch over oral formulation, leading to less 
dry mouth. In addition, controlled release from transdermal formulations for the musca-
rinic receptor resulted in longer duration of action, albeit with slower onset (29).
Histopathology in t he bladder infl ammation model
Fig. 5a shows the morphology of a healthy normal urinary bladder consisting of mul-
tilayers of transitional cell epithelium, sub-mucosa and muscle layers. Fig. 5b and 5c give 
the microscopic picture of the group treated with 0.75 % acetic acid. Necrosis of the tran-
sitional cells and fl at ulcer atrophy of the mucosa epithelium with the presence of neutro-
phils and lymphocytes suggest acute infl ammation. This demonstrates that acetic acid has 
caused damage to the bladder. Fig. 5d provides microscopic information for the group that 
was treated with acetic acid and received oral TT treatment. It shows near normal urinary 
bladder with no evidence of infl ammatory cells, which confi rms the positive healing eff ect 
of oral tolterodine. Fig. 5e and 5f give the microscope picture for groups treated with TT 
transdermal patches. Focal areas of necrosis and ulceration of the mucosa with mild to 
moderate infl ammation in sub-mucosa indicates bett er healing process in C1 and slow 
healing in E1.
While the urinary bladder of the former was normal and intact, the latt er displayed 
transitional cell necrosis, infl ammatory infi ltration and ulceration of mucosa, indicating 
acute cystitis. However, the oral TT treated animals had near normal structures in the 
bladder, indicating complete healing. Histopathology of the urinary bladder of the C1 
treated group exhibited fast regeneration of the transitional epithelium while the E1 treat-
ed group with a similar bladder structure as C1 displayed mild ulceration in mucosa with 
scatt ered infl ammation. However, slides from the transdermal matrix patch revealed in-
fl ammation in the bladder with mild to moderate infl ammation in sub-mucosa indicating 
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the beginning of the healing process. Nevertheless, it was slower than oral TT, which may 
be explained as follows: fi rst, since transdermal patch formulation followed the controlled-
release patt ern, it took time for the drug to reach the target site. Hence, a further 24-hour 
study is required to evaluate the complete healing eff ect. Second, the drug loading was 
insuffi  cient to produce a signifi cant therapeutic eff ect due to the smaller area available for 
patch application on rat skin compared to humans. Anyhow, drug loading can be aug-
mented by increasing the drug concentration or patch application area.
CONCLUSIONS
Analysis of our experimental data fi ndings suggest that, amongst the transdermal 
patches studied, the C1 patch (Eudragit E 100/PVP/DBP) had the most eff ective polymer 
Fig. 5. Representative micrographs from rat bladders taken immediately aft er micturition studies: a) 
control (normal) group, b) acetic acid treated group showing edema, c) acetic acid treated group 
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and plasticizer combination. This polymeric matrix patch, which had the ideal physico-
chemical and mechanical and in vitro permeation profi les, could be applied directly to the 
skin for t he OAB therapy. In vivo studies revealed that the C1 patch treated animals not 
only had higher salivary secretion but also achieved faster epithelial bladder regeneration 
compared to the E1 formulation. Thus, this study has established the eff ectiveness of trans-
dermal TT matrix patch formulations in treating OAB in addition to reducing the dry 
mouth eff ects. Results also showed the feasibility of tolterodine tartrate transdermal deliv-
ery in OAB treatment. Further work on establishing the effi  cacy of therapeutic activity of 
the drug is to be carried out via pharmacokinetic and pharmacodynamic studies.
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